WHY: Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities ...

Fintel reports that on May 16, 2025, UBS downgraded their outlook for Iovance Biotherapeutics (BIT:1IOVA) from Buy to Neutral. There are 524 funds or institutions reporting positions in Iovance ...

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Iovance Biotherapeutics. The Motley Fool has a disclosure policy.

Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA) securities between ...

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for ...

NEW YORK – After securing $25.6 million in Series B financing this week, Tilt Biotherapeutics has sufficient resources to continue advancing its oncolytic viral therapy, TILT-123, as a treatment for ...

THOUSAND OAKS, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to ...

Elliott, which holds a $2.5 billion stake in Phillips 66, has been pushing for major changes at the company, including the potential spin-off or sale of its midstream business, and is seeking to ...

Host Asma Khalid talks with author Clover Hope about Missy Elliott’s impact, from “Get Ur Freak On” to “1, 2 Step.” Hope is the author of “The Motherlode: 100+ Women Who Made Hip-Hop.” ...